Applicant, as named in the Orange Book
Apellis Pharms
Next listed expiry: Empaveli on 14 Dec 2038. 2 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Empaveli NDA 215014 pegcetacoplan | 14 Dec 2038 patent |
| Syfovre NDA 217171 pegcetacoplan | 14 Dec 2038 patent |
Recent events
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.